Clinical Trial Update: Pazopanib Versus Sunitinib in the Treatment of Asian Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial results comparing pazopanib to sunitinib in Asian patients with locally advanced or metastatic renal cell carcinoma were reported; the study is co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Sutent (sunitinib)
• Votrient (Pazopanib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Carcinoma, Renal Cell | Phase 2 | Status: COMPLETED | Results posted: 2013-03-15